Simulation of phase III studies of motesanib 125 mg once daily (QD) plus carboplatin/paclitaxel (CPM) or bevacizumab plus carboplatin/paclitaxel (CPB) versus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results